Carisma’s CT-0508 (HER2 CAR-Macrophage) Receives Fast Track Designation From the FDA
On Wednesday, September 22, Carisma announced (press release) that the FDA has granted Fast Track designation to CT-0508 (HER2-targeting CAR-Macrophage) for HER2-overexpressing solid tumors. Below, Celltelligence provides insights on how CT-0508 could benefit from Fast Track designation, while discussing the potential advantages of CAR-Macrophages (CAR-M).
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.